CalciMedica, Inc.

For the period ended Jun 30, 2026. Filed Aug 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 11, 2026

CALC$1.37-9.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(in thousands, except share amounts)

Common Stock · AdditionalPaid-In · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’
	Shares	Amount	Capital	Deficit	Loss	Equity (Deficit)
Balance—January 1, 2026	15,437,410	$4	$182,681	$(189,326)	$—	$(6,641)
Stock-based compensation expense	—	—	561	—	—	561
Issuance of common stock from exercise of warrants	306,506	—	—	—	—	—
Vesting of restricted stock units	2,500	—	—	—	—	—
Net income	—	—	—	4,976	—	4,976
Balance—March 31, 2026	15,746,416	$4	$183,242	$(184,350)	$—	$(1,104)
Stock-based compensation expense	—	—	540	—	—	540
Issuance of common shares from private placement (net of issuance costs)	14,938,370	2	10,697	—	—	10,699
Issuance of warrants in connection with the private placement	—	—	3,000	—	—	3,000
Issuance of common stock from at-the-market offering (net of issuance costs)	49,115	—	31	—	—	31
Vesting of restricted stock units	2,500	—	—	—	—	—
Unrealized loss on investments	—	—	—	—	(1)	(1)
Net loss	—	—	—	(7,652)	—	(7,652)
Balance—June 30, 2026	30,736,401	$6	$197,510	$(192,002)	$(1)	$5,513

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · AdditionalPaid-In · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’
	Shares	Amount	Capital	Deficit	Gain (Loss)	Equity
Balance—January 1, 2025	13,481,917	$4	$174,166	$(159,764)	$4	$14,410
Stock-based compensation expense	—	—	549	—	—	549
Issuance of common shares from underwritten public offering (net of issuance costs)	—	—	8	—	—	8
Issuance of common stock from at-the-market offering (net of issuance costs)	490,073	—	968	—	—	968
Unrealized loss on investments	—	—	—	—	(5)	(5)
Net loss	—	—	—	(5,042)	—	(5,042)
Balance—March 31, 2025	13,971,990	$4	$175,691	$(164,806)	$(1)	$10,888
Stock-based compensation expense	—	—	1,174	—	—	1,174
Unrealized loss on investments	—	—	—	—	(3)	(3)
Net loss	—	—	—	(5,956)	—	(5,956)
Balance—June 30, 2025	13,971,990	$4	$176,865	$(170,762)	$(4)	$6,103

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.